Delving into the Latest Updates on RK-33 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

DDX3X

Mechanism

DDX3X inhibitors(ATP-dependent RNA helicase DDX3X inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Lung Cancer

Inactive Indication-

Originator Organization

The Johns Hopkins University

Active Organization

The Johns Hopkins University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC23H20N6O3

InChIKeyCOUMZXFUZDBRCZ-UHFFFAOYSA-N

CAS Registry1070773-09-9

Patients who present with breast cancer bone metastasis only have limited palliative treatment strategies and efficacious drug treatments are needed. In breast cancer patient data, high levels of the RNA helicase DDX3 are associated with poor overall survival and bone metastasis. Consequently, our objective was to target DDX3 in a mouse breast cancer bone metastasis model using a small molecule inhibitor of DDX3, RK-33. Histologically confirmed live imaging indicated no bone metastases in the RK-33 treated cohort, as opposed to placebo-treated mice. We generated a cell line from a bone metastatic lesion in mouse and found that it along with a patient-derived bone metastasis cell line gained resistance to conventional chemotherapeutics but not to RK-33. Finally, differential levels of DDX3 were observed in breast cancer patient metastatic bone samples. Overall, this study indicates that DDX3 is a relevant clinical target in breast cancer bone metastasis and that RK-33 can be a safe and effective treatment for these patients.

100 Deals associated with RK-33

Login to view more data